Osimertinib demonstrated superior cost-effectiveness and emerged as the optimal treatment for patients with unresectable stage III EGFR-mutated NSCLC without disease progression after chemoradiotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.